The overarching hypothesis of our project is that clinical meaningful improvements in survival for PDA will require targeting multiple compartments within the pancreas cancer neo-organ, including hematopoietic cells, mesenchymal cells and the extracellular matrix, in addition to the tumor epithelial cell. We propose to test specific regimens combining matrix disruption, myeloid cell inhibition or maturation, mesenchymal cell inhibition, and cytotoxic chemotherapy across four distinct experimental platforms that provide complementary strengths and mitigate limitations: 1) genetically engineered mouse models (GEMM) of autochthonous PDA; 2) syngeneic allografts; 3) patient-derived xenograft (PDX) systems; and 4) patient-derived organoids (PDO). For more information click here